Here is a complete breakdown of what is needed, why, and where to get it done
AY reports receiving speaker fees from Teva, UK, outside the submitted work
While formal evidence remains in development, the mechanistic rationale is compelling: sustained, gentle GLP-1 receptor activation may favorably influence glucose metabolism, cardiovascular integrity, and neuroprotection, all while maintaining tolerability and adherence
It appears to be very potent, meaning that very low doses can be used, and this is scalable
We interpret the clinical and mechanistic data obtained for different agents that enable weight loss and glucose control for the treatment of obesity and type 2 diabetes mellitus, respectively, by activating or blocking GIPR signalling, including the GIPRGLP1R co-agonist tirzepatide, as well as the GIPR antagonistGLP1R agonist AMG-133
In addition, exenatide was shown to activate GLP-1R and inhibit the PI3K/AKT pathway to inhibit the growth, migration, and invasion of ovarian cancer cells, and promote cell apoptosis, thereby producing anticancer effects on diabetic patients with ovarian cancer (218)